206 related articles for article (PubMed ID: 14593724)
1. From DNA damage to G2 arrest: the many roles of topoisomerase II.
Larsen AK; Escargueil AE; Skladanowski A
Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724
[TBL] [Abstract][Full Text] [Related]
2. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/.
Downes CS; Clarke DJ; Mullinger AM; Giménez-Abián JF; Creighton AM; Johnson RT
Nature; 1994 Dec; 372(6505):467-70. PubMed ID: 7984241
[TBL] [Abstract][Full Text] [Related]
3. G2 arrest in response to topoisomerase II inhibitors: the role of p53.
Clifford B; Beljin M; Stark GR; Taylor WR
Cancer Res; 2003 Jul; 63(14):4074-81. PubMed ID: 12874009
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.
Zhou Y; Gwadry FG; Reinhold WC; Miller LD; Smith LH; Scherf U; Liu ET; Kohn KW; Pommier Y; Weinstein JN
Cancer Res; 2002 Mar; 62(6):1688-95. PubMed ID: 11912141
[TBL] [Abstract][Full Text] [Related]
5. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy.
Anderson HJ; Andersen RJ; Roberge M
Prog Cell Cycle Res; 2003; 5():423-30. PubMed ID: 14593736
[TBL] [Abstract][Full Text] [Related]
7. Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine.
Ferguson LR; Whiteside G; Holdaway KM; Baguley BC
Environ Mol Mutagen; 1996; 27(4):255-62. PubMed ID: 8665870
[TBL] [Abstract][Full Text] [Related]
8. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs.
Potter AJ; Rabinovitch PS
Mutat Res; 2005 May; 572(1-2):27-44. PubMed ID: 15790488
[TBL] [Abstract][Full Text] [Related]
9. Novel carbamate derivatives of 4-beta-amino-4'-O-demethyl-4-desoxypodophyllotoxin as inhibitors of topoisomerase II: synthesis and biological evaluation.
Duca M; Arimondo PB; Léonce S; Pierré A; Pfeiffer B; Monneret C; Dauzonne D
Org Biomol Chem; 2005 Mar; 3(6):1074-80. PubMed ID: 15750651
[TBL] [Abstract][Full Text] [Related]
10. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Chen M; Beck WT
Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
[TBL] [Abstract][Full Text] [Related]
11. Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity.
Agostinho M; Santos V; Ferreira F; Costa R; Cardoso J; Pinheiro I; Rino J; Jaffray E; Hay RT; Ferreira J
Cancer Res; 2008 Apr; 68(7):2409-18. PubMed ID: 18381449
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II inhibitors.
Clapp JM; Hande KR
Cancer Chemother Biol Response Modif; 2002; 20():125-49. PubMed ID: 12703203
[No Abstract] [Full Text] [Related]
14. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest.
Wesierska-Gadek J; Schloffer D; Gueorguieva M; Uhl M; Skladanowski A
Cancer Res; 2004 Jul; 64(13):4487-97. PubMed ID: 15231658
[TBL] [Abstract][Full Text] [Related]
15. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
16. Multilevel therapeutic targeting by topoisomerase inhibitors.
Smith PJ; Souès S
Br J Cancer Suppl; 1994 Sep; 23():S47-51. PubMed ID: 8075006
[TBL] [Abstract][Full Text] [Related]
17. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines.
Schmidt F; Knobbe CB; Frank B; Wolburg H; Weller M
Oncol Rep; 2008 Apr; 19(4):1061-6. PubMed ID: 18357397
[TBL] [Abstract][Full Text] [Related]
18. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
Withoff S; De Jong S; De Vries EG; Mulder NH
Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
[TBL] [Abstract][Full Text] [Related]
19. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
[TBL] [Abstract][Full Text] [Related]
20. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells.
Snyder RD
Environ Mol Mutagen; 2000; 35(1):13-21. PubMed ID: 10692223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
